Cardlytics (CDLX) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
1 Dec, 2025Executive summary
Revised proxy statement filed to include required Inline XBRL data tagging previously omitted.
Risk oversight and compliance
Insider Trading Policy restricts directors, officers, employees, and consultants from short sales, options, hedging, margin accounts, and pledging company securities.
Policy aims to ensure compliance with insider trading laws and exchange listing standards.
Board of directors and corporate governance
Insider Trading Policy applies to both employees and non-employee board members.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Cardlytics
- Revenue and billings fell, but operational gains and U.K. growth support optimism for 2026.CDLX
Q4 20254 Mar 2026 - Revenue down 9% but net loss narrowed as platform modernization and transformation continue.CDLXQ2 20242 Feb 2026
- Q3 revenue fell 15% to $67.1M, with a $145M net loss from impairment charges.CDLXQ3 202416 Jan 2026
- Q4 beat guidance despite a 10% revenue drop; 2025 targets sequential gains and profitability.CDLXQ4 202424 Dec 2025
- Proxy covers director elections, auditor ratification, new equity plan, and executive pay reforms.CDLXProxy Filing1 Dec 2025
- Preliminary proxy statement outlines voting matters and governance, with no major capital changes.CDLXProxy Filing1 Dec 2025
- Revenue dropped 8.4% but net loss narrowed as user base grew and cost controls took effect.CDLXQ1 202526 Nov 2025
- Q2 revenue fell 9% as billings and net loss worsened; Q3 billings to drop 15%-22%.CDLXQ2 202523 Nov 2025
- Revenue and billings dropped, but net loss narrowed and user growth remained strong.CDLXQ3 202513 Nov 2025